<DOC>
	<DOC>NCT02445586</DOC>
	<brief_summary>Study of Pertuzumab (In Combination with Trastuzumab and Docetaxel) in Indian Patients with Breast Cancer</brief_summary>
	<brief_title>Safety Study of Pertuzumab (In Combination With Trastuzumab and Docetaxel) in Indian Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1. Male or female patients aged &gt;/= 18 years 2. Signed written informed consent approved by the relevant Institutional Review Board/Ethics Committee, prior to any study procedure 3. For women of childbearing potential and men with partners of childbearing potential, agreement to use a highlyeffective nonhormonal form of contraception or two effective forms of nonhormonal contraception by the patient and/or partner. 4. Histologically or cytologically confirmed and documented adenocarcinoma of the breast with metastatic or locally recurrent disease not amenable to curative resection; patients with measurable and/or nonmeasurable disease are eligible 5. Known and documented HER2positive 6. Known and documented left ventricular ejection fraction (LVEF) of at least 50% 7. Adequate organ function 1. Previous systemic nonhormonal anticancer therapy for the metastatic or locally recurrent disease 2. Pregnant or lactating women 3. Current clinical or radiographic evidence of central nervous system (CNS) metastases 4. Disease progression while receiving or within 12 months of completion of trastuzumab and/or lapatinib treatment in the adjuvant or neoadjuvant setting</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>